Atrial-Fixation TMVR Appears Feasible, Durable at 1 Year
The AltaValve system, featuring a novel atrial fixation mechanism, shows promise for high-risk patients undergoing transcatheter mitral valve replacement (TMVR). An early feasibility study demonstrated significant reductions in mitral regurgitation and improved clinical outcomes at one year. The device aims to expand access to TMVR for patients who are typically ineligible for conventional procedures due to anatomical challenges.
- ▪The AltaValve system was tested in a study involving 30 high-risk patients across Europe, the US, and Japan.
- ▪At one year, all patients had none or trace regurgitation immediately post-procedure, with 95% maintaining mild or trace regurgitation.
- ▪The study reported no new-onset atrial fibrillation or stroke in either patient group during the follow-up period.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/atrial-fixation-tmvr-appears-feasible-durable-1-year-2026a1000geq?src=rss |
| Publication time | Wed, 20 May 2026 17:50:14 EDT |
| Retrieval time | 2026-05-20T22:05:03.081Z |
| Last seen | 2026-05-20T22:05:03.081Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | MOSxTP_XZs2Y |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
High-risk patients treated with the AltaValve system, which employs a novel atrial fixation mechanism, had sustained reductions in mitral regurgitation at 1 year and improved clinical outcomes in an early feasibility study. The company hopes the device will make transcatheter mitral valve replacement (TMVR) accessible to more patients, including those who would not be eligible for conventional TMVR.When Subvalvular TMVR Falls ShortSurgery and guideline-directed medical therapy remain the standard of care for mitral regurgitation, but mitral transcatheter edge-to-edge repair (mTEER) has become a preferred option for patients at high surgical risk or with refractory heart failure.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
